Physician profile
Omotola A Hope
NPI 1477649184
$62,906.68
in general payments reported to CMS, 2019-2025
62 companies · $3,904 in 2025
The $3,904 reported for 2025 was more than what 82% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $101 · 2021: $1,495 · 2022: $22K · 2023: $22K · 2024: $13K · 2025: $3,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $24K · Food and Beverage: $14K · Travel and Lodging: $1,210 · Education: $33.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $23,900.00 |
| Food and Beverage | $13,986.73 |
| Travel and Lodging | $1,209.66 |
| Education | $33.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $46,651.78 | 2021-2025 | Xcopri |
| Abbvie INC. | $2,888.87 | 2021-2025 | |
| Ucb, INC. | $1,917.62 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Novartis Pharmaceuticals Corporation | $988.74 | 2021-2025 | |
| Pfizer INC. | $885.60 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $854.44 | 2022-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $665.79 | 2022-2025 | Mavenclad |
| Eisai INC. | $592.57 | 2020-2025 | |
| Abbott Laboratories | $517.78 | 2023-2024 | Infinity |
| Biogen, INC. | $517.62 | 2021-2025 | Vumerity, Tysabri, Plegridy |
| Acadia Pharmaceuticals INC | $515.00 | 2021-2025 | Nuplazid |
| Lilly USA, LLC | $447.34 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Alexion Pharmaceuticals, INC. | $427.81 | 2022-2024 | Ultomiris |
| Allergan, INC. | $346.29 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $344.00 | 2022-2025 | Hyqvia |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omotola Hope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.